JP4777602B2 - ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置 - Google Patents

ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置 Download PDF

Info

Publication number
JP4777602B2
JP4777602B2 JP2002559066A JP2002559066A JP4777602B2 JP 4777602 B2 JP4777602 B2 JP 4777602B2 JP 2002559066 A JP2002559066 A JP 2002559066A JP 2002559066 A JP2002559066 A JP 2002559066A JP 4777602 B2 JP4777602 B2 JP 4777602B2
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002559066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521893A (ja
JP2004521893A5 (enExample
Inventor
テディー コソグロー，
ハリー アール． デイビス，
ギレス ジーン バーナード ピカード，
ウィン−キー フィリップ チョー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26950511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4777602(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004521893A publication Critical patent/JP2004521893A/ja
Publication of JP2004521893A5 publication Critical patent/JP2004521893A5/ja
Application granted granted Critical
Publication of JP4777602B2 publication Critical patent/JP4777602B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002559066A 2001-01-26 2002-01-25 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置 Expired - Lifetime JP4777602B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26439601P 2001-01-26 2001-01-26
US60/264,396 2001-01-26
US32383901P 2001-09-21 2001-09-21
US60/323,839 2001-09-21
PCT/US2002/002009 WO2002058732A2 (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007141163A Division JP4937836B2 (ja) 2001-01-26 2007-05-28 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2007293724A Division JP2008088184A (ja) 2001-01-26 2007-11-12 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置

Publications (3)

Publication Number Publication Date
JP2004521893A JP2004521893A (ja) 2004-07-22
JP2004521893A5 JP2004521893A5 (enExample) 2005-05-26
JP4777602B2 true JP4777602B2 (ja) 2011-09-21

Family

ID=26950511

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002559066A Expired - Lifetime JP4777602B2 (ja) 2001-01-26 2002-01-25 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2007141163A Expired - Lifetime JP4937836B2 (ja) 2001-01-26 2007-05-28 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2007293724A Pending JP2008088184A (ja) 2001-01-26 2007-11-12 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2012018544A Withdrawn JP2012087149A (ja) 2001-01-26 2012-01-31 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2007141163A Expired - Lifetime JP4937836B2 (ja) 2001-01-26 2007-05-28 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2007293724A Pending JP2008088184A (ja) 2001-01-26 2007-11-12 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2012018544A Withdrawn JP2012087149A (ja) 2001-01-26 2012-01-31 ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置

Country Status (32)

Country Link
US (5) US20020151536A1 (enExample)
EP (2) EP1413331B1 (enExample)
JP (4) JP4777602B2 (enExample)
KR (1) KR100596257B1 (enExample)
CN (1) CN100509058C (enExample)
AR (2) AR033855A1 (enExample)
AT (2) ATE348649T1 (enExample)
AU (1) AU2002247019C1 (enExample)
BR (1) BR0206654A (enExample)
CA (3) CA2562982C (enExample)
CL (1) CL2004001174A1 (enExample)
CY (2) CY1108000T1 (enExample)
CZ (2) CZ301871B6 (enExample)
DE (2) DE60222773T2 (enExample)
DK (2) DK1353696T3 (enExample)
EC (1) ECSP11004702A (enExample)
ES (2) ES2274013T3 (enExample)
HU (2) HU230253B1 (enExample)
IL (3) IL156445A0 (enExample)
ME (1) MEP27808A (enExample)
MX (1) MXPA03006725A (enExample)
NO (1) NO331512B1 (enExample)
NZ (1) NZ525921A (enExample)
PL (1) PL208110B1 (enExample)
PT (2) PT1413331E (enExample)
RS (2) RS51449B (enExample)
RU (1) RU2356550C2 (enExample)
SI (2) SI1413331T1 (enExample)
SK (2) SK287988B6 (enExample)
TW (1) TWI337083B (enExample)
WO (1) WO2002058732A2 (enExample)
ZA (1) ZA200305693B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
RU2756946C2 (ru) 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Применение замещенных азетидинонов для лечения ситостеролемии
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR034204A1 (es) * 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
AU2002247019C1 (en) 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7407772B2 (en) 2001-09-24 2008-08-05 Merck & Co., Inc. Screening and selection methods for statin drug combinations
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
NZ539624A (en) * 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
EP1574215B1 (en) * 2002-12-16 2015-07-15 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
WO2004069193A2 (en) * 2003-02-03 2004-08-19 Thomas Jefferson University Methods and compositions for inhibiting cholesterol uptake
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
JP4688819B2 (ja) 2003-12-23 2011-05-25 アストラゼネカ アクチボラグ コレステロール吸収阻害活性を有するジフェニルアゼチジノン誘導体
CA2553769C (en) * 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
US20070116645A1 (en) * 2004-02-03 2007-05-24 Steven Farber Methods and compositions for inhibiting cholesterol uptake
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
CN101495106A (zh) * 2005-07-18 2009-07-29 瑞莱恩特医药品有限公司 用基于氮杂环丁酮的胆固醇吸收抑制剂和ω-3脂肪酸进行的治疗及其组合产品
WO2007100807A2 (en) * 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
ATE530178T1 (de) * 2007-05-23 2011-11-15 Amcol International Corp Mit cholesterin interagierende phyllosilikate und verfahren zur reduktion von hypercholesterinämie bei einem säuger
US8858994B2 (en) 2007-12-10 2014-10-14 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
PL2229938T3 (pl) 2009-03-13 2012-09-28 Sanovel Ilac Sanayi Ve Ticaret As Kompozycje ezetymibu
EP2414529A2 (en) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
SG11201501740XA (en) 2012-09-27 2015-04-29 Kowa Co Therapeutic agent for dyslipidemia
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN104337785A (zh) * 2014-11-04 2015-02-11 万全万特制药江苏有限公司 一种含有依折麦布的口腔崩解片及其制备方法
CN105213340A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种依折麦布片及其制备方法
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CN106310173A (zh) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
CN109718215A (zh) * 2017-10-30 2019-05-07 海南皇隆制药股份有限公司 一种依折麦布片
KR101983298B1 (ko) * 2018-06-11 2019-05-29 연세대학교 산학협력단 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물

Family Cites Families (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1286A (en) * 1839-08-13 Richard else
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US3108097A (en) * 1963-10-22 Ehnojs
FR1103113A (fr) 1954-04-15 1955-10-31 Triméthylol-alcanes et leur procédé de préparation
FR1217929A (fr) 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
NL238796A (enExample) * 1958-05-07
DE1302648B (enExample) 1960-09-27
NL127065C (enExample) * 1964-04-22
NL137318C (enExample) * 1964-06-09
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
FI52570C (fi) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
FR2408577A1 (fr) 1977-11-14 1979-06-08 Devinter Sa Nouveau procede de synthese d'esters para chlorobenzoyl phenoxy isobutyriques
NZ191762A (en) 1978-10-19 1982-09-14 Merck & Co Inc Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
FR2494112B1 (enExample) 1980-11-19 1986-01-10 Laruelle Claude
DE3107100A1 (de) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
DE3484362D1 (de) * 1983-03-28 1991-05-08 Ciba Geigy Ag Verfahren zur herstellung von optisch aktiven azetidinonen.
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1985004876A1 (fr) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. Derives de 2-azetidinone et leur procede de preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH0679559B2 (ja) 1985-06-06 1994-10-12 三共株式会社 光学活性アゼチジノン誘導体の製法
JPH01501470A (ja) 1986-01-23 1989-05-25 ジ・アップジョン・カンパニ− 抗菌性ｎ−アシル−２−アゼチジノン
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
KR880701098A (ko) 1986-04-01 1988-07-25 로버어트 에이 아미테이지 메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
FR2598146B1 (fr) * 1986-04-30 1989-01-20 Rech Ind Nouveau procede de preparation de fibrates.
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
JPS6317859A (ja) 1986-07-11 1988-01-25 Sagami Chem Res Center フルオロアゼチジノン誘導体
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
CN87107149A (zh) 1986-10-03 1988-05-18 伊莱利利公司 7-[(间位取代的)苯基甘氨酸]1-碳代-1-去硫头孢菌素
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
PH25145A (en) * 1986-12-15 1991-02-19 Laverne Dwaine Boeck Process for producing the a10255 complex and corresponding microorganism
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
ES2052584T3 (es) 1986-12-15 1994-07-16 Lilly Co Eli El complejo antibiotico a10255 y factores, proceso, microorganismos para su produccion.
JPS63156788A (ja) 1986-12-22 1988-06-29 Sanraku Inc 光学活性アゼチジノン類
WO1988005296A2 (en) 1987-01-27 1988-07-28 Warner-Lambert Company Lpid regulating compositions
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4879301A (en) * 1987-04-28 1989-11-07 Hoei Pharmaceutical Co., Ltd. Antiallergic and antiinflammatory benzothiazolinone derivatives
GB8710965D0 (en) 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
YU46699B (sh) 1987-10-06 1994-04-05 Eli Lilly And Co. Kristalni monohidratni oblik 1-karbacefalosporina
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
US5385885A (en) 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
IL89835A0 (en) 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
CA2002596A1 (en) 1988-11-14 1990-05-14 Thomas M. Eckrich Hydrates of b-lactam antibiotic
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
IL95574A (en) 1989-09-09 1994-11-11 Knoll Ag Colestyramine preparation
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
CA2039763A1 (en) 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2042526A1 (en) 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
ZA915372B (en) * 1990-07-17 1993-03-31 Lilly Co Eli Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
CA2048395A1 (en) 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5075313A (en) 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2640986B2 (ja) * 1990-11-08 1997-08-13 高砂香料工業株式会社 （１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
IT1244699B (it) 1991-02-01 1994-08-08 Luso Farmaco Inst Processo per la preparazione di acidi 3 acilammino-4- carbamoilossimetil-2-azetidinone-l-solfonici ed intermedi per la loro preparazione
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
AU658441B2 (en) 1991-07-23 1995-04-13 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
JP2620437B2 (ja) 1991-09-27 1997-06-11 宇部興産株式会社 ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
JPH06511250A (ja) 1991-10-04 1994-12-15 ザ、プロクター、エンド、ギャンブル、カンパニー コレステロール低下化合物及びそれらの製造方法
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
HUT67035A (en) 1991-11-25 1995-01-30 Pfizer New process for the production of steroidal glycosides derivatives
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
JPH07504921A (ja) 1992-06-26 1995-06-01 フアイザー・インコーポレイテツド 高コレステロール血症を治療するためのステロイドグリコシド
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
WO1994010143A1 (en) 1992-10-27 1994-05-11 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5631363A (en) 1992-11-13 1997-05-20 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
WO1994020535A1 (en) 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5358852A (en) 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5563264A (en) 1993-02-10 1996-10-08 Shionogi & Co., Ltd. Preparation of βlactam compounds
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
IL109568A0 (en) 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE69428280T2 (de) 1993-07-09 2002-06-13 Schering Corp., Kenilworth Verfahren zur herstellung von azetidinonen
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
WO1995004533A2 (en) 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
AU7397094A (en) 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
CA2180148A1 (en) 1993-12-28 1995-07-06 Michael Paul Deninno Hypocholesterolemic agents
US6369103B1 (en) 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9406074D0 (en) 1994-03-26 1994-05-18 Glaxo Spa Chemical process
DE4414538A1 (de) 1994-04-26 1995-11-02 Klinge Co Chem Pharm Fab Präparate zur Therapie der kombinierten Hyperlipidämie mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem Fibrat
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
JPH10501811A (ja) * 1994-06-20 1998-02-17 シェーリング コーポレイション 低コレステロール化剤として有用な置換アゼチジノン化合物
US6429289B1 (en) 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
CA2200436A1 (en) 1994-09-20 1996-04-04 Pfizer Inc. Combination therapy for hypercholesterolemia
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
FI972584L (fi) 1994-12-22 1997-08-19 Smithkline Beecham Plc Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
PT801564E (pt) 1994-12-28 2002-09-30 Janssen Pharmaceutica Nv Utilizacao de nebivolol como agente anti-aterogernico
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5998441A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5639739A (en) 1995-03-24 1997-06-17 The Dupont Merck Pharmaceutical Company Imidazole containing aminoboronic acids
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
DE19518988A1 (de) 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5612378A (en) 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5612353A (en) 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
AU6039296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
NO318765B1 (no) 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
US5698527A (en) 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
FR2738817B1 (fr) 1995-09-14 1997-10-17 Adir Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
CN1103780C (zh) 1995-10-31 2003-03-26 先灵公司 用作降低血胆固醇药剂的糖取代2－氮杂环丁酮
US5808056A (en) 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5955105A (en) 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US5925333A (en) 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
JPH09143156A (ja) 1995-11-17 1997-06-03 Tanabe Seiyaku Co Ltd アセトキシアゼチジノン誘導体の製法及びその合成中間体
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19608750A1 (de) 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
CA2251972A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
CA2252696A1 (en) 1996-04-26 1997-11-06 Deirdre Mary Bernadette Hickey Azetidinone derivatives for the treatment of atherosclerosis
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
CA2255663C (en) * 1996-05-24 2002-08-20 Schering Corporation Antifungal composition with enhanced bioavailability
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
GB9611947D0 (en) 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US5998421A (en) 1996-06-12 1999-12-07 Kyowa Hakko Kogyo Co., Ltd. Lipid metabolism ameliorants
US5965553A (en) 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
AU4228997A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US5952003A (en) 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
EP0930882A2 (en) 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US6057342A (en) 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5959123A (en) 1996-09-23 1999-09-28 Synphar Laboratories, Inc. 3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
KR100353304B1 (ko) 1996-10-01 2002-09-30 에스알아이 인터내셔널 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ES2230624T5 (es) 1996-11-27 2010-10-25 Aventis Pharmaceuticals Inc. Composicion farmaceutica que comprende un compuesto que tiene actividad anti-xa y un compuesto antagonista de la agregacion plaquetaria.
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
EP0989852A4 (en) 1997-01-17 2002-11-13 Bristol Myers Squibb Co METHODS FOR TREATING ATHEROSCLEROSE THROUGH AN MPT INHIBITOR AND CHOLESTEROL LEVELS LOWERING MEDICINES
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
EP2251036A1 (en) * 1997-02-28 2010-11-17 Sanofi Pasteur Biologics Co. Chimeric flavivirus vaccines
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
CA2285091A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
DE19716120A1 (de) 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
AU735760B2 (en) 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
DE69829966T2 (de) 1997-05-14 2006-02-09 Atherogenics, Inc. Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US6300364B1 (en) 1997-07-24 2001-10-09 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
DE69837610T2 (de) 1997-07-31 2008-01-03 Kos Life Sciences, Inc., Weston Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6117429A (en) 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5886191A (en) 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
CA2300165A1 (en) 1997-08-26 1999-03-04 Merck & Co., Inc. Cholesterol-lowering therapy
WO2001018210A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US6180660B1 (en) 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6143885A (en) 1997-08-27 2000-11-07 Merck & Co., Inc. Preparation of beta-methyl carbapenem intermediates
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
JP2001515887A (ja) 1997-09-09 2001-09-25 デュポン ファーマシューティカルズ カンパニー Ｘａ因子の阻害剤としての、ベンゾイミダゾリノン類、ベンゾオキサゾリノン類、ベンゾピペラジノン類、インダノン類、およびそれらの誘導体
AU8996698A (en) 1997-09-10 1999-03-29 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
GB2329334A (en) 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
CA2214895C (en) 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
AU9002798A (en) 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
CA2304505A1 (en) 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
IE970731A1 (en) 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US6242439B1 (en) 1997-10-07 2001-06-05 Boehringer Ingelheim (Canada) Ltd. Azetidinone derivatives for the treatment of HCMV infections
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
EP1030665A4 (en) 1997-10-17 2002-11-27 Aventis Pharm Prod Inc THERAPEUTIC USE OF CHINOLINE DERIVATIVES
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO1999022728A1 (en) 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
AU1809499A (en) 1997-12-10 1999-06-28 Awadhesh K. Mishra Self-emulsifying fenofibrate formulations
US5985936A (en) 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
NZ505761A (en) 1998-01-28 2003-08-29 Warner Lambert Co Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
AU1887999A (en) 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
KR100620337B1 (ko) 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1289475C (zh) 1998-04-29 2006-12-13 奥索-麦克尼尔药品公司 在肥胖症和其它病症的治疗中用作神经肽yy5受体配体的n－取代的氨基1,2,3,4－四氢化萘
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2779347A1 (fr) 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
EP1089731A4 (en) 1998-06-24 2003-06-18 Merck & Co Inc COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
EP1089732A4 (en) 1998-06-24 2001-09-19 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
US6099865A (en) 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
FR2781222A1 (fr) 1998-07-17 2000-01-21 Lipha Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation
DE69911975T2 (de) 1998-07-31 2004-09-09 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
DE69929345T2 (de) 1998-08-07 2006-09-21 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Substituierte isoxal-derivate als östrogenrezeptormodulatoren
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
FR2783421B1 (fr) 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
BR9914098A (pt) 1998-09-30 2001-07-31 Warner Lambert Co Método para impedir ou retardar revascularização à base de cateter
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123268A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123267A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023425A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
JP2002527520A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
CA2253769C (en) 1998-11-10 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising fenofibrate
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
WO2000031548A1 (en) 1998-11-25 2000-06-02 Scios Inc. Prevention and treatment of amyloid-associated disorders
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
JP3640888B2 (ja) 1998-12-07 2005-04-20 シェーリング コーポレイション アゼチジノンの合成プロセス
US6277584B1 (en) 1998-12-16 2001-08-21 Dade Behring Inc. Method for calibrating a chemical analyzer with improved accuracy at low signal levels
EP1140036A2 (en) 1998-12-18 2001-10-10 Abbott Laboratories Novel formulations comprising lipid-regulating agents
DE19858789A1 (de) 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
DK1140191T3 (da) 1998-12-23 2003-02-24 Searle Llc Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer
WO2000038724A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU779264B2 (en) * 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
WO2000038728A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
EA005815B1 (ru) 1998-12-23 2005-06-30 Джи.Ди.Сирл Ллс Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний
ATE242008T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
ATE240120T1 (de) 1998-12-23 2003-05-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
WO2000050392A1 (en) 1999-02-24 2000-08-31 Sankyo Company, Limited 2-mercaptocarboxylic acid derivatives
AU2866400A (en) 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
EP1036563A1 (en) 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
EP1637137A3 (en) 1999-03-10 2006-07-05 G.D. Searle LLC Method and composition for administering a cyclooxygenase-2 inhibitor to animals
TR200202077T2 (tr) 1999-03-11 2002-11-21 Nuclear Receptor Research Limited Prar nükleer reseptörleri için yeni ligandlar
EP1175246A4 (en) 1999-03-19 2004-12-15 Brigham & Womens Hospital POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE OF TYPE III ENDOTHELIAL CELLS BY HMG-COA REDUCTASE INHIBITORS
WO2000057918A2 (en) 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
JP2003520767A (ja) 1999-03-31 2003-07-08 アボット・ラボラトリーズ 脂質調整剤を含む新規製剤
JP3679715B2 (ja) 1999-04-05 2005-08-03 シェーリング コーポレイション １−（４−フルオロフェニル）−３（ｒ）−［３（ｓ）−ヒドロキシ−３−（４−フルオロフェニル）プロピル）］−４（ｓ）−（４−ヒドロキシフェニル）−２−アゼチジノンの調製のための立体選択的微生物還元
US6593078B1 (en) 1999-04-16 2003-07-15 Schering Corporation Use of azetidinone compounds
JP2002542224A (ja) 1999-04-19 2002-12-10 コーエラカント コーポレイション Ｉｉ型糖尿病の治療薬としてのｐｐａｒ−（ガンマ）作用物質
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
BR0009864A (pt) 1999-04-20 2002-01-08 Novo Nordisk As Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
JP2002542237A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
CA2270306C (en) 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6033656A (en) 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
WO2000069445A1 (en) 1999-05-13 2000-11-23 Geltex Pharmaceuticals, Inc. Combination therapy for treating hypercholesterolemia
HK1044897A1 (zh) 1999-05-14 2002-11-08 Esperion Luv Development Inc. 心绞痛和/或不典型心绞痛的治疗方法及其相关药物组合物和药剂盒
JP2003500439A (ja) 1999-05-28 2003-01-07 アボット・ラボラトリーズ 脂質調節剤を含む新規調合物
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
GB9913782D0 (en) 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
US6380191B1 (en) 1999-06-18 2002-04-30 Merck & Co. Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP4295458B2 (ja) 1999-06-30 2009-07-15 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ活性調節用化合物
AU4491200A (en) 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
AU778720B2 (en) 1999-08-23 2004-12-16 Kyorin Pharmaceutical Co. Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
AU778723B2 (en) 1999-08-23 2004-12-16 Kyorin Pharmaceutical Co. Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
CA2382573C (en) 1999-08-23 2007-05-22 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
CA2381926A1 (en) 1999-08-31 2001-03-08 Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
ES2215719T3 (es) 1999-09-08 2004-10-16 Glaxo Group Limited Antagonista ppar oxazol.
US6174665B1 (en) 1999-09-10 2001-01-16 Biex, Inc. Hormone replacement therapy monitoring
ATE316071T1 (de) 1999-09-17 2006-02-15 Kyorin Seiyaku Kk O-anisamid-derivate
EP1225901A2 (en) 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
EP1214351A2 (en) 1999-09-22 2002-06-19 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
DE69923718T2 (de) 1999-09-24 2006-01-12 Kyorin Pharmaceutical Co., Ltd. Ppar-alpha und ppar-gamma-hemmer
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
AU2833701A (en) 1999-09-30 2001-05-10 Shell Internationale Research Maatschappij B.V. Adducts of glycidylesters of alpha, alpha-branched carboxylic acids and carboxylic acids and poly(ortho ester) as intermediate for their preparation
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2001030343A1 (en) 1999-10-22 2001-05-03 Merck & Co., Inc. Pharmaceuticals for treating obesity
NZ518822A (en) 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
CA2390557A1 (en) 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
JP2003514024A (ja) 1999-11-12 2003-04-15 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性疾患の治療のためのウイルス
WO2001040192A1 (en) 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
DE60019741T2 (de) 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
ATE312613T1 (de) 2000-02-29 2005-12-15 Bristol Myers Squibb Co Niedrig dosierte entecavir formulierung und deren verwendung
CA2406077C (en) 2000-04-10 2010-07-20 Nicholas J. Wald Formulation for the prevention of cardiovascular disease
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
US20020132855A1 (en) * 2000-08-03 2002-09-19 Nelson Edward B. Use of acetaminophen to prevent and treat arteriosclerosis
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
AU2001292874B2 (en) * 2000-09-27 2006-06-15 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2002231049B2 (en) 2000-12-20 2006-07-20 Merck Sharp & Dohme Corp. Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1217927C (zh) * 2000-12-21 2005-09-07 阿文蒂斯药物德国有限公司 新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
HRP20030501A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AU2002247019C1 (en) 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE369851T1 (de) 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
CN1582168A (zh) 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
ES2296894T3 (es) 2001-01-26 2008-05-01 Schering Corporation Combinaciones de ezetimiba con aspirina para tratar estados vasculares.
AR034204A1 (es) 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
RU2756946C2 (ru) 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Применение замещенных азетидинонов для лечения ситостеролемии
CA2437118A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10106787A1 (de) 2001-02-12 2002-08-22 Nanogate Gmbh Wasserfrei hydrolisierte Sol-Gel-Systeme
EP1372632A1 (en) 2001-02-15 2004-01-02 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
EP1389114A2 (en) * 2001-03-08 2004-02-18 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
US7348334B2 (en) * 2001-04-09 2008-03-25 Dr. Reddy's Laboratories Limited Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1392287B8 (en) 2001-05-25 2007-01-10 Schering Corporation Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1420826A2 (de) 2001-08-22 2004-05-26 Aventis Pharma Deutschland GmbH Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
EP1425018B1 (de) 2001-08-22 2008-10-22 Sanofi-Aventis Deutschland GmbH Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
DE60229406D1 (de) 2001-09-21 2008-11-27 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US20030119808A1 (en) 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2003039542A1 (en) 2001-10-17 2003-05-15 Merck & Co. Inc. Combination therapy for treating alzheimer's disease
US20050123580A1 (en) 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
AU2003225027A1 (en) 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist

Also Published As

Publication number Publication date
YU58603A (sh) 2006-05-25
CZ2010307A3 (enExample) 2004-01-14
CZ309209B6 (cs) 2022-05-25
AU2002247019B2 (en) 2006-08-03
IL191417A (en) 2011-12-29
HUP0303915A2 (hu) 2004-03-01
WO2002058732A2 (en) 2002-08-01
WO2002058732B1 (en) 2003-09-12
CZ301871B6 (cs) 2010-07-14
EP1353696B1 (en) 2006-12-20
PL368653A1 (en) 2005-04-04
RU2003126184A (ru) 2005-03-10
JP2004521893A (ja) 2004-07-22
CA2562982A1 (en) 2002-08-01
JP2007211031A (ja) 2007-08-23
NO331512B1 (no) 2012-01-16
HUP0303915A3 (en) 2012-12-28
US20060199793A1 (en) 2006-09-07
AR064012A2 (es) 2009-03-04
CA2563051A1 (en) 2002-08-01
HK1063607A1 (en) 2005-01-07
IL156445A (en) 2010-11-30
EP1413331A3 (en) 2004-06-30
US20050153952A1 (en) 2005-07-14
RU2008144912A (ru) 2010-05-20
ATE348649T1 (de) 2007-01-15
EP1353696A2 (en) 2003-10-22
HU230253B1 (hu) 2015-11-30
ES2274013T3 (es) 2007-05-16
US20020151536A1 (en) 2002-10-17
US7030106B2 (en) 2006-04-18
CN1646165A (zh) 2005-07-27
PT1353696E (pt) 2007-02-28
RS51449B (sr) 2011-04-30
CA2434682C (en) 2008-11-18
PT1413331E (pt) 2007-12-18
US7612058B2 (en) 2009-11-03
TWI337083B (en) 2011-02-11
DK1353696T3 (da) 2007-04-10
CY1107045T1 (el) 2012-09-26
CN100509058C (zh) 2009-07-08
RS20100015A (sr) 2010-12-31
SI1413331T1 (sl) 2008-02-29
JP2012087149A (ja) 2012-05-10
SI1353696T1 (sl) 2007-04-30
EP1413331A2 (en) 2004-04-28
AU2002247019C1 (en) 2017-05-11
NO20033355D0 (no) 2003-07-25
MXPA03006725A (es) 2003-10-24
SK9482003A3 (en) 2003-12-02
CL2004001174A1 (es) 2005-05-06
RU2356550C2 (ru) 2009-05-27
AR033855A1 (es) 2004-01-07
EP1413331B1 (en) 2007-10-03
DE60216890T2 (de) 2007-08-30
CA2562982C (en) 2011-03-15
ZA200305693B (en) 2005-04-26
BR0206654A (pt) 2004-02-25
DK1413331T3 (da) 2007-12-10
HK1056696A1 (en) 2004-02-27
IL156445A0 (en) 2004-01-04
SK287988B6 (sk) 2012-09-03
KR100596257B1 (ko) 2006-07-03
ATE374641T1 (de) 2007-10-15
NZ525921A (en) 2005-06-24
DE60222773T2 (de) 2008-07-17
US20020192203A1 (en) 2002-12-19
CY1108000T1 (el) 2013-09-04
KR20040025887A (ko) 2004-03-26
ES2290562T3 (es) 2008-02-16
WO2002058732A3 (en) 2003-07-03
JP4937836B2 (ja) 2012-05-23
CA2434682A1 (en) 2002-08-01
DE60216890D1 (de) 2007-02-01
PL208110B1 (pl) 2011-03-31
DE60222773D1 (de) 2007-11-15
US20080058306A1 (en) 2008-03-06
CZ20032030A3 (cs) 2004-01-14
MEP27808A (en) 2010-10-10
JP2008088184A (ja) 2008-04-17
NO20033355L (no) 2003-07-25
ECSP11004702A (es) 2011-03-31
SK288217B6 (sk) 2014-08-05

Similar Documents

Publication Publication Date Title
JP4777602B2 (ja) ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
AU2002247019B9 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP4711600B2 (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
JP4395370B2 (ja) ステロール吸収阻害剤を使用して血管炎症を治療または予防する方法
JP2004521894A (ja) 胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
JP2004517916A (ja) ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
AU2002247019A1 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP2005504091A (ja) ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
CN101297969B (zh) 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
AU2007201970B2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2006202618B9 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
RU2483724C2 (ru) Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов
AU2008201609B8 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
HK1115810A (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20071217

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110630

R150 Certificate of patent or registration of utility model

Ref document number: 4777602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140708

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term